Attention Deficit Disorder with Hyperactivity - 737 Studies Found
| Completed |
: A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting : Attention Deficit Hyperactivity Disorder : 2015-08-07 :
|
| Completed |
: Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes : Attention-Deficit/Hyperactivity Disorder : 2005-09-12 : Drug: Atomoxetine |
| Completed |
: Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD) : Attention Deficit Hyperactivity Disorder : 2008-10-14 : Drug: Methylphenidate Comparison of two extended-release formulations of 20mg Methylphenidate in a cross |
| Completed |
: Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD : Attention-Deficit/Hyperactivity Disorder : 2006-09-28 : Drug: Phosphatidylserine-Omega3 |
| Completed |
: A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting : Attention Deficit Hyperactivity Disorder : 2015-07-07 : Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules HLD200 doses: 20, 40, 60, 80 or 100 mg |
| Completed |
: Pilot Trial Comparing Computerised Cognitive Exercises to Tetris in Adolescents With ADHD : Attention Deficit/Hyperactivity Disorder : 2016-03-24 :
|
| Completed |
: A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale) : Attention-Deficit/Hyperactivity Disorder : 2009-04-20 |
| Completed |
: Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD) : Attention Deficit Hyperactivity Disorder (ADHD) : 2011-05-20 :
|
| Enrolling by invitation |
: Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With ADHD : Attention-deficit/Hyperactivity Disorder. : 2014-04-04 :
|
| Completed |
: Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility : Attention Deficit Hyperactivity Disorder : 2009-08-04 : Drug: Atomoxetine In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based |